MMP7 as a prospective marker of pancreatic carcinoma.

V Roškovičová, I Večurkovská, J Kaťuchová, J Mašlanková, P Bohuš, V Kaťuch

Abstract read

In one paragraph

Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Integrative multi-cohort analysis of DNA methylation profiles for pancreatic ductal adenocarcinoma biomarker discovery and prognosis.Frontiers in bioinformatics · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

V Roškovičová1, Department of Surgery, Medical Faculty, P.J.Šafárik University and University Hospital, Košice, Slovakia.

I VečurkovskáDepartment of Medical and Clinical Biochemistry, Medical Faculty, P.J.Šafárik University, Košice, Slovakia. ivana.vecurkovska@upjs.sk.ORCID http://orcid.org/0000-0002-1600-4116

J Kaťuchová1, Department of Surgery, Medical Faculty, P.J.Šafárik University and University Hospital, Košice, Slovakia.

J MašlankováDepartment of Medical and Clinical Biochemistry, Medical Faculty, P.J.Šafárik University, Košice, Slovakia.

P BohušDepartment of Pathology, Medical Faculty, P.J.Šafárik University, Košice, Slovakia.

V KaťuchDepartment of Neurosurgery, Medical Faculty, P.J.Šafárik University and University Hospital, Košice, Slovakia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic carcinoma is a serious oncological disease with high mortality due to late diagnosis. Therefore, there is currently a high priority in research to discover a biomarker that can reliably diagnose pancreatic cancer at the earliest stage. 46 patients (35 patients with pancreatic tumor, 11 patients with inflammatory pancreatic diseases) were involved in this prospective study. Blood serum and tissue samples were analyzed by zymography to determine the active and inactive forms of MMP7. The difference in the level of the inactive form of MMP7 between the groups of patients with malignant and benign findings was statistically significant.

Indexed as

CarcinomaMMP7PancreasPrognosis

Identifiers

PMID41649727

DOI10.3390/biology9040080

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.